Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19855323 | 0.95 | THRB (0.51) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL19855124 | 0.90 | MEN1 (0.41) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL19854071 | 0.89 | RARB (0.48) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL23635441 | 0.88 | PTPN11 (0.43) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL19854434 | 0.87 | RARB (0.47) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL19855892 | 0.86 | THRA (0.54) | MEN1ALDH1A1KMT2ATHRBTHRA | |
| SCHEMBL19855896 | 0.84 | THRB (0.54) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL19855805 | 0.82 | PTPN11 (0.45) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL19855955 | 0.81 | THRB (0.45) | MEN1ALDH1A1KMT2ATHRBTHRA | |
| SCHEMBL20370616 | 0.81 | THRB (0.45) | MEN1ALDH1A1KMT2ATHRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
| WO-2018025974-A1 | LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE | JNC株式会社 | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, MBD2, PAXBP1 | MEN1 73/4885USP2 3524/4885ALDH1A1 3826/4885 |
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | SP1, MBD2, PAXBP1 | MEN1 73/4885USP2 3524/4885ALDH1A1 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.